Since the introduction of cisplatin into combination chemotherapy for the treatment of patients with metastatic germ cell tumours of the testis (GCTT) most centres have reported a 30% improvement in the overall survivals without major changes in chemotherapy regimens.`3 This improvement has been due to reduction in the incidence of deaths related to treatment as a result ofincreasing experience using the regimen, particularly dose intensity of treatment, avoiding delay between treatments, and the judicious use of surgical staging after completion of chemotherapy. Furthermore, treating earlier stage cases due to greater confidence in the ability to produce close to 100% cure of small volume disease, and dispensing with radiotherapy as treatment of choice for stage I and II disease, has also contributed to better survival.
Despite these major advances in patient management, residual retroperitoneal masses may remain. Lymphangiography, intravenous urography, ultrasound, computerised tomography scanning and Accepted for publication 25 Until recently, patients with metastatic GCTT were treated by orchidectomy and either radical lymph node dissection (para-aortic or mediastinal or both) or radiotherapy. As modem chemotherapy for metastatic disease is extremely effective, clinicians have questioned the need for routine retroperitoneal node dissection with its associated risks to the patient of damage to the great vessels'4 and loss of ejaculation.5 Even after radiotherapy there is a risk of death due to marrow toxicity induced by chemotherapy. Various techniques have been used to establish if metastatic testicular carcinoma remains within the retroperitoneal lymph nodes after chemotherapy. Most promise has been shown by measuring serum concentrations of the tumour markers fi-chorionic gonadotrophin and a-fetoprotein. When positive, they have a good correlation with histopathological type but there isn't a 100% correlation between detection in serum and detection in tissue.'617 Therefore, the characteristics of retroperitoneal tissues can only be accurately determined by thorough histological examination after surgical excision.
In our study the histological analysis of retroperitoneal tissues shows that malignant teratoma undifferentiated, malignant teratoma intermediate, and malignant teratoma trophoblastic was present in 13 of 52 (25%) patients who had surgical excision. This finding emphasises the fact that once the course of chemotherapy has been completed retroperitoneal nodes may still contain residual disease which provides foci for disease relapse.
In patients showing mature teratoma in retroperitoneal nodes the prognosis was good. Only one died of his disease and the other of intercurrent illness. In the first patient the mass was incompletely excised. Several cases have been reported of the late relapse of mature teratoma both as a GCTT and as sarcomatous or carcinomatous transformation within a mature teratoma.'" This is emphasised by the finding that one of our cases with mature teratoma in retroperitoneal tissues developed areas of squamous carcinoma and rhabdomyosarcoma. Loehrer et al also reported that in patients in whom it was not possible to remove all mature teratoma, one third were found to have relapsed within five years. '8 The prognosis was also good for patients in our series with fibronecrotic tissue in retroperitoneal nodes. Only two patients died, one due to intercurrent illness and the other with metastatic disease; in the latter case the fibronecrotic tissue was incompletely excised. Therefore, there remains the possibility that although resected tissue appears totally necrotic histologically, micrometastases of viable tumour may remain undetected leading to disease relapse.
We would therefore advise that retroperitoneal node dissection be considered in the management of patients with advanced GCTT after completion of chemotherapy, and that if it is to be perfomed it must be emphasised that as complete a resection as possible should be attempted. Retroperitoneal dissection with resection is a dangerous surgical procedure but the overall morbidity and mortality are low. 4 In conclusion, we have shown that with increasing experience in the use of combination chemotherapy, patients with metastatic undifferentiated testicular cancer seem to have better disease free survivals than those with intermediate differentiated tumours, and close to that ofmetastatic seminoma. Retroperitoneal masses remaining after completion of chemotherapy can only be determined accurately by thorough histological examination. Patients with well differentiated testicular tumours on presentation have a high chance of harbouring residual active disease within retroperitoneal tissues after chemotherapy. If mature teratoma or fibronecrotic tissue is present then these patients do have a good prognosis, but the evidence available suggests that if either of these elements remain there is a slight chance of disease relapse, particularly if excision is incomplete. We advise that thorough resection of retroperitoneal nodes be considered in the management of all patients with advanced GCTT following completion of chemotherapy.
